Premium
P2‐080: Serum glutamine synthetase has no value as a diagnostic biomarker for Alzheimer's disease
Author(s) -
Vermeiren Yannick,
Le Bastard Nathalie,
Clark Christopher,
Engelborghs Sebastiaan,
De Deyn Peter
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.970
Subject(s) - biomarker , medicine , cerebrospinal fluid , disease , lumbar puncture , neurology , glutamine , alzheimer's disease , urine , gastroenterology , psychiatry , biology , biochemistry , amino acid
r value1⁄4 -0.43). Linear combinations of centroid frequency and SNI values based on multivariate modeling accurately tracked ADAS-Cog changes with a highly significant r value of 0.99. Conclusions: It was possible to extract and characterize multiple features of resting-state MEG scans that changed in concert with changes in the ADAS-Cog over the course of 10 months. These results demonstrate the utility of resting-state MEG scans for tracking the progression of AD over periods of less than a year. Additional longitudinal testing of this and additional patient cohorts will support continued improvement of disease severity models based on resting-state MEG.